Embryonic stem (ES) cell-derived cardiomyocytes (ESCMs) must be specifically purified in order to prevent teratoma formation, and this confusing issue has hampered their clinical application. We therefore investigated a technique to generate pure labeled ESCMs for possible use in cardiac repair. We generated transgenic ES cell lines expressing enhanced green fluorescent protein ( 
INTRODUCTION
Because the regenerative capacity of adult cardiac tissue is limited, any substantial cell loss or dysfunction, such as that occurring during myocardial infarction, is generally irreversible. Such damage may lead to progressive heart failure, a leading cause of mortality worldwide. Cell therapy to replace lost or damaged tissue in the dysfunctional zone is a promising therapeutic approach by which to restore cardiac function. Embryonic stem cells are uniquely endowed with the capacity of self-renewal and can differentiate into cells of all three germ lineages, including beating cardiomyocytes (CMs) (1) . ES cell transplantation reduces post-myocardial infarction remodeling and improves cardiac function, suggesting that ES cells hold promise for myocardial cellular therapy (2) .
Although ES cells are a promising source for cell replacement therapy, many issues need to be resolved before they can be applied clinically. Several reports demonstrated that only ~5% of the cells within embryoid bodies (EBs) spontaneously differentiate into ES cell-derived CMs (ESCMs) (3, 4) , so clinical CM transplantation requires a large-scale production of suitable donor cells. Therefore, many studies have been undertaken to develop strategies for differentiating early CMs from ES cells (5, 6) . Additionally, ESCMs must be specifically purified to prevent teratoma formation.
In an attempt to produce ESCMs, we studied their in vitro generation from transgenic ES cell lines expressing enhanced green fluorescent protein (EGFP) under the transcriptional control of the α-cardiac myosin heavy chain (α-MHC) promoter. We also investigated using neuregulin-1 (NRG-1), a member of the epidermal growth factor (EGF/ErbB) family, to enhance the differentiation process.
RESULTS

Characteristics of EGFP-positive cells derived from selected ES cell clones
We electroporated undifferentiated ES cells with a pα-MHC p / EGFP construct. After the ES cells recovered for 24 h in ES medium, they were given 400 μg/ml G418 in the culture medium. After one to two days of selection, the cultures looked like fairly dense ES cell cultures (Fig. 1a) . We began to observe cell death after three to four days of selection, and after five to seven days, most of the unwanted ES cell colonies had died, and many dead cells were floating or loosely adherent. After seven to ten days of selection, small round colonies became visible in the dish (Fig. 1b) . About 20 G418-resistant ES cell clones were amplified and differentiated through this process.
EBs formed during suspension ( Fig. 1c-d) ; most attached to culture plates within 24 h, became flattened, and formed thin multilayered structures. Beginning at day 8 of differentiation, clusters of spontaneously-beating ESCMs appeared in the outgrowths of several EBs (Fig. 1e) , and fluorescence microscopy revealed EGFP-positive cells in the beating foci (Fig. 1f) . Immunohistoche-http://bmbreports.org mistry revealed that almost all of these EGFP-positive cells also exhibited positive staining for cardiac troponin T (Fig. 2a) .
Effect of NRG-1 on differentiation of CMs from ES cell clones
NRG-1 (100 ng/ml) significantly upregulated the mRNA levels of the early cardiac-restricted transcription factors Nkx2.5 and GATA-4 after seven days of differentiation (Fig. 2b) . The mRNA levels of cardiac-specific α-MHC and β-MHC increased during the early to middle developmental stages (from day 8 to day 12 of differentiation), regardless of whether the cultures contained 100 ng/ml NRG-1 (Fig. 2c ), but levels in the NRG-1 treated group were significantly higher than control levels.
NRG-1 enhanced the expression of cardiac troponin T within the EB beating foci
Synchronously beating foci in EBs, with or without NRG-1 treatment, exhibited characteristics of CMs, as demonstrated by immunostaining with an antibody directed against cardiac http://bmbreports.org BMB reports troponin T. However, NRG-1 treatment significantly increased the cardiac troponin T-positive area ( Fig. 3a-b ).
DISCUSSION
Spontaneous in vitro differentiation of ESCs into CMs normally requires an initial two-day aggregation step to form EBs in hanging droplets, followed by suspension for five days, before cells are plated onto gelatin-coated tissue culture dishes (7) (8) (9) . Within one to four days after plating, some EBs form in one or more of the beating foci, and these structures contain cells termed ESCMs. However, differentiating EBs may contain cells from all three germ lineages, with ESCMs comprising only a minority of the entire cell population. Therefore, much effort has been invested in developing strategies to label and purify ESCMs, so that they can be developed for clinical heart disease applications (10-13). Herein, we describe a feasible method for labeling ES cell-derived CMs. With the help of the cardiac-specific α-MHC promoter driving an EGFP reporter gene, we specifically stained CMs in differentiated ES cells. Additionally, treatment with the growth factor NRG-1 greatly enhanced CM differentiation, as seen in the upregulated early cardiac markers in our immunohistochemistry results. We chose the 5.5-kb α-MHC promoter, because α-MHC mRNA is found exclusively in the early stages of the developing heart and is active throughout the entire developing heart (14, 15) .
Beginning with undifferentiated ES cells that harbored a plasmid carrying EGFP under the control of an α-MHC promoter sequence, we amplified neomycin-resistant ES cell clones. We observed EGFP-positive cells in spontaneouslybeating foci beginning at day 8 of differentiation ( Fig. 1) , almost all of which also exhibited positive staining for cardiac troponin T (Fig. 2a); i.e., they displayed characteristics of CMs. Kolossov et al. used patch-clamp analysis to show EGFP expression exclusively in pacemaker and atrial cells, but not ventricular cells (16) . Thus, these EGFP-positive cells could be used as a biological pacemaker to repair a damaged cardiac conduction system. Increasing evidence has shown that NRG-1/heregulin-1 (NRG-1/HRG-1), a member of the EGF family, is vital for heart development (17-19). Our NRG-1 treatment significantly upregulated the early cardiac-restricted transcription factors Nkx2.5 and GATA-4 in EBs differentiated from ES cell clones (Fig. 2b) . Moreover, NRG-1 treatment increased cardiac-specific transcription of α-MHC and β-MHC between days 8 and 12 of development (Fig. 2c) . Immunostaining analysis also confirmed that NRG-1 treatment significantly increased the cardiac troponin T-positive area within the differentiated EBs (Fig. 3) . Thus, exogenous NRG-1 promoted CM differentiation of geneticallyengineered ES cell clones at an early stage of differentiation.
Developing EBs express ErbB receptors, and while the NRG-1/ErbB signaling axis is clearly important in heart development, the underlying molecular mechanism is still poorly understood (20) (21) (22) . Recently, Kim et al. In summary, herein we described a potential technique for labeling and enriching the EB cell population for ES cell-derived CMs, This approach, a combined use of genetically-engineered ES cell clones and exogenous growth factor treatment, could be used to develop a cell population suitable for transplantation.
MATERIALS AND METHODS
Vector construct and cell clone generation
The pcDNA3.0 and pEGFP-N1 vectors were purchased from Invitrogen (Carlsbad, CA, USA) and Clontech (Palo Alto, CA, USA), respectively. The EGFP fragment was removed from pEGFP-N1 by double digestion with XhoI and XbaI (Takara, Japan) and inserted into the multiple cloning site of the pcDNA3.0 vector to obtain the pcDNA3.0/EGFP construct. The human cytomegalovirus (CMV) promoter was removed by double digestion with XhoI and BalII (Takara, Japan), and the vector was recircularized by blunt-end ligation to obtain the pcDNA3.0 /EGFP/ΔCMV construct.
The vector containing a 5.5-kb fragment of the α-MHC gene, including exons 1-2 (untranslated), part of exon 3, and the 5' upstream regulatory element with the last 3' untranslated exons from the neighboring β-MHC gene, was kindly provided by Dr. J. Robbins (Cincinnati, OH) (24) . The fragment was excised using BamHI and SalI (Takara, Japan) and blunt-end ligated into the pcDNA3.0/EGFP/ΔCMV construct to generate the pα-MHC p / EGFP construct. The correct tail-to-head orientation of the promoter to the coding sequence of EGFP in pα-MHC p /EGFP was confirmed by sequencing analysis. To generate the α-MHC ES cell line, the construct was electroporated into D3 ES cells (ATCC, CRL 1934) at 500 μF and 240 V using a Bio-Rad Gene Pulser TM (Munich, Germany). The transfected clones were selected with 400 μg/ml neomycin treatment as described previously (25) .
Cell culture and differentiation
Undifferentiated ES cells from the G418-selected cell clones were grown on mitotically-inactivated mouse embryonic fibroblast (MEF) feeder layers in Dulbecco's modified Eagle medium (DMEM; Gibco/BRL, USA) supplemented with 15% fetal bovine serum (FBS, HyClone, USA), 50 U/ml penicillin, 50 μg/ml streptomycin (Gibco/BRL), 2 mM L-glutamine (Gibco/BRL), 10 μM β-mercaptoethanol (β-ME, Gibco/BRL), 0.1 mM non-essential amino acids (NEAAs, Gibco/BRL), and 1000 U/ml leukemia inhibitory factor (LIF, Chemicon, USA). MEF layers were harvested from embryos of 13.5-day pregnant ICR mice (Slaccas, Shanghai Institute for Biological Sciences) using a previouslydescribed method (citation). The study was approved by the Ethics Committee of Shanghai Jiaotong University School of Medicine. Animal handling was conducted in accordance with the Declaration of Helsinki and the Guiding Principles in the Care and Use of Animals.
In brief, an ES cell suspension containing 2 × 10 4 cells/ml was prepared in DMEM supplemented with 20% FBS, 50 U/ml penicillin, 50 μg/ml streptomysin, 2 mM L-glutamine, 10 μM β-ME, and 0.1 mM NEAAs. Cell droplets (400 cells/drop) were placed on the lids of bacterial petri dishes for two days to form EBs. EBs were transferred to new bacterial petri dishes containing fresh differentiation medium. On day 7, individual EBs were transferred to gelatin-coated 24-well tissue culture plates for terminal differentiation. Differentiating EBs were observed daily under a phase-contrast microscope for the presence of beating CMs.
To examine the effect of NRG-1 on cardiac differentiation, a recombinant peptide containing the β variant of the EGF-like domain of NRG-1 (Peprotech, USA) was added to the differentiation medium at a final concentration of 100 ng/ml from day 3 to day 7.
Semi-quantitative RT-PCR
Using TRIzol Reagent (Invitrogen) according to the manufacturer's instructions, total RNA was extracted from EBs on day 7 of the suspension culture or from beating EB outgrowths on day 8 to 12 of expansion. An aliquot of 2 μg total RNA was reverse transcribed using M-MLV reverse transcriptase (Invitrogen) with random primers, according to the manufacturer's recommended protocol. The RT product (1 μl) was then amplified by PCR using specific primers designed with Primer Premier 5.0 (Premier, Canada). PCR amplification conditions were as follows: an initial denaturation at 95 Table 1 . PCR products were separated on 2% agarose gels containing 0.001% ethidium bromide. The fluorescent densities of the resulting bands were determined with Quantity One software (Bio-Rad, USA) and normalized to that of β-actin.
Immunhistochemistry
Whole EBs were plated on 1% gelatin-coated coverslips and fixed with 4% paraformaldehyde for 15 min at room temperature. Samples were permeabilized with 0.25% Triton-X100 (Sigma, St. Louis, MO) for 10 min. Blocking was performed in 1% bovine serum albumin (BSA, Sigma), after which samples were incubated with an antibody against cardiac troponin T (diluted 1:100; Thermo Scientific, USA) overnight at 4 o C. After extensive washing, EBs were exposed to a Cy3-conjugated secondary antibody (diluted 1:100; Solomon Biotechnology, China) at room temperature for 60 min. DAPI was used to counterstain the nuclei. Samples were mounted with aqueous mounting medium (DAKO, USA) and fluorescently imaged with a Nikon imaging system (Yokohama, Japan). Immunostained areas were quantified with Image-Pro Plus 5.0 (Media Cybernetics, USA) and normalized to the total surface area of each EB.
Statistical analysis
Data are expressed as means ± S.E.M. of at least three independent experiments. Statistical analyses were conducted with one-way ANOVA or Student's t test. A P ＜ 0.05 was considered statistically significant.
